drugset / Trial / NCT06855147

Mass Balance Study of [14C]HRS9531 in Healthy Male Subjects

NCT06855147

Phase 1 Completed 7 enrolled Fujian Shengdi Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This study was a single-center, single-dose, open-label study in healthy male subjects to investigate the absorption, metabolism and excretion of HRS9531 after a single subcutaneous injection of \[14C\]HRS9531.

Timeline

Start
2025-04-21
Primary completion
2025-06-17
Completion
2025-06-17

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS9531 Unknown Subcutaneous